Ignite Creation Date:
2025-12-26 @ 4:01 PM
Ignite Modification Date:
2025-12-31 @ 10:36 PM
Study NCT ID:
NCT02054806
Status:
COMPLETED
Last Update Posted:
2023-10-30
First Post:
2014-02-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-02-17
Start Date Type:
ACTUAL
Primary Completion Date:
2021-04-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-04-30
Completion Date Type:
ACTUAL
First Submit Date:
2014-02-03
First Submit QC Date:
None
Study First Post Date:
2014-02-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-04-19
Results First Submit QC Date:
None
Results First Post Date:
2023-10-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-06
Last Update Post Date:
2023-10-30
Last Update Post Date Type:
ACTUAL